Patterns of β-blocker utilization in patients with chronic heart failure: Experience from a specialized outpatient heart failure clinic

American Heart Journal

Volumn 147, Issue 1, 2004, Pages 79-83

  Gupta, Ritesh ^a   Tang, W H Wilson ^a   Young, James B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; SPIRONOLACTONE; VASODILATOR AGENT;

ADULT; AGE; AGED; ARTICLE; BRADYCARDIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INFORMATION; DRUG UTILIZATION; DRUG WITHDRAWAL; ELECTRONICS; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH CARE QUALITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOGLYCEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORBIDITY; OUTPATIENT DEPARTMENT; PHYSICIAN; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL; TITRIMETRY; TREATMENT OUTCOME; VERTIGO;

EID: 0346156032     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.07.022     Document Type: Article

References (23)

1. Young JB, Weiner DH, Yusuf S, et al. Patterns of medication use in patients with heart failure: a report from the registry of Studies of Left Ventricular Dysfunction (SOLVD). South Med J 1995;88:514-23.
2. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction: results from the SPICE registry. Eur Heart J 1999;20:1182-90.
3. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
4. CIBIS-II Investigators and Committees. The cardiac insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999;353:9-13.
5. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
6. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000;283:1295-1302.
7. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. 3-Year follow-up of patients randomized in the Metoprolol in Dilated Cardiomyopathy Trial. Lancet 1998;351:1180-1.
8. The Australia and New Zealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
9. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
10. Albert NM, Young JB. Heart failure disease management: a team approach. Cleve Clin J Med 2001;68:53-62.
11. Grady KL, Dracup K, Kennedy G, et al. Team management of patients with heart failure: a statement for healthcare professionals from the Cardiovascular Nursing Council of the American Heart Association. Circulation 2000;102:2443-56.
12. American Thoracic Society. Standardization of spirometry: 1994 Update. ATS Statement. Am J Respir Crit Care Med 1995;152:1107-36.
13. National Center for Health Statistics. NHANES III reference manuals and reports. Hyattsville, Md: Data Dissemination Branch; 1996. CD-ROM No. 6-0178 (1096).
14. Hankinson JL, Bang KM. Acceptability and reproducibility criteria of the American Thoracic Society as observed in a sample of the general population. Am Rev Respir Dis 1991;143:516-21.
15. Sharpe N. Translation of clinical trial results into practice. Eur Heart J 1998;19(Suppl L):L28-32.
16. Hobbs FD. Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients? Br J Gen Pract 2000;50:735-42.
17. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
18. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation In Cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002;40:111-8.
19. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat versus Enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 2002;106:920-6.
20. Farrell MH, Foody JM, Krumholz HM. Beta-blockers in heart failure: clinical applications. JAMA 2002;287:890-7.
21. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease (Cochrane Review). Cochrane Database Syst Rev 2002;1:CD002992.
22. Chen J, Radford MJ, Wang Y, et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001;37:1950-6.
23. Salpeter S, Ormiston T, Salpeter E, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease (Cochrane Review). Cochrane Database Syst Rev 2002;3:CD003566.